Christopher J. Damman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher J. Damman has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Juan P. Frias
Velocity Clinical Research Los Angeles California USA
2 shared publicationsMarc E. Washington
Supergut Los Angeles California USA
2 shared publicationsMartin L. Lee
UCLA Fielding School of Public Health Los Angeles California USA
2 shared publicationsSamuel I Miller
Department of Microbiology, University of Washington, Seattle, Washington, 98195, United States of America
2 shared publicationsTimothy L Zisman
Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington, 98195, United States of America
2 shared publications- Arturo Casadevall
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Elsevier in Current Developments in Nutrition
- Vol. 10 (7)
A Nutrient Ratio-Based, Web-Enabled Food Quality Score Is Associated With Weight and Blood Pressure Compared With Leading Nutrient Profiling Systems
- 29 May 2026
- Published by Elsevier in Current Developments in Nutrition
- Vol. 10 (7)
Open AccessA Nutrient Ratio-Based, Web-Enabled Food Quality Score Is Associated With Weight and Blood Pressure Compared With Leading Nutrient Profiling Systems
- Top Cited PapersOpen Access
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (7)
Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver disease worldwide, and our understanding of its pathogenesis continues to evolve. MASLD progresses from steatosis to steatohepatitis, fibrosis, and cirrhosis, and this Review explores how the gut microbiome and their metabolites contribute to MASLD pathogenesis. We explore the complexity and importance of the intestinal barrier function and how disruptions of the intestinal barrier and dysbiosis work in concert to promote the onset and progression of MASLD. The Review focuses on specific bacterial, viral, and fungal communities that impact the trajectory of MASLD and how specific metabolites (including ethanol, bile acids, short chain fatty acids, and other metabolites) contribute to disease pathogenesis. Finally, we underscore how knowledge of the interaction between gut microbes and the intestinal barrier may be leveraged for MASLD microbial-based therapeutics. Here, we include a discussion of the therapeutic potential of prebiotics, probiotics, postbiotics, and microbial-derived metabolites.
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (7)
Top Cited PapersOpen AccessMetabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver disease worldwide, and our understanding of its pathogenesis continues to evolve. MASLD progresses from steatosis to steatohepatitis, fibrosis, and cirrhosis, and this Review explores how the gut microbiome and their metabolites contribute to MASLD pathogenesis. We explore the complexity and importance of the intestinal barrier function and how disruptions of the intestinal barrier and dysbiosis work in concert to promote the onset and progression of MASLD. The Review focuses on specific bacterial, viral, and fungal communities that impact the trajectory of MASLD and how specific metabolites (including ethanol, bile acids, short chain fatty acids, and other metabolites) contribute to disease pathogenesis. Finally, we underscore how knowledge of the interaction between gut microbes and the intestinal barrier may be leveraged for MASLD microbial-based therapeutics. Here, we include a discussion of the therapeutic potential of prebiotics, probiotics, postbiotics, and microbial-derived metabolites.
- Open Access
A Nutrient Ratio–Based, Web-Enabled Food Quality Score Performs Favorably Compared with Leading Nutrient Profiling Systems for Weight and Blood Pressure
Background Obesity is on the rise, driven in part by changing patterns in food consumption. Nutrient profiling systems (NPSs) aim to guide healthier food choices through labeling and consumer facing technologies that highlight food quality. Objectives This study compares four leading NPSs—Nutri-Score (NS), Health Star (HS), NOVA Classification (NC), Food Compass 2.0 (FC) – with nutrient ratios and a nutrient-ratio-based NPS, Nutrient Consume Score (NCS), for their associations with obesity and blood pressure in the U.S. population using NHANES data. Methods NHANES (2015–2016) was analyzed for adults aged 20 and older. Dietary intake was assessed via 24-hour recalls, and NPS scores were calculated. Multivariable regression models adjusted for lifestyle factors were used to assess associations with obesity and blood pressure measures. Results All NPSs and nutrient ratios were significantly correlated with healthier weight and showed variable associations with blood pressure. Incorporating alcohol and adjusting for bioactives in a ratio-based NPS improved its association with weight outcomes. The food categories contributing to high and low scores were largely consistent across NPSs. Conclusions The NPSs and nutrient ratios evaluated were significantly associated with obesity and blood pressure measures. Intervention studies offering real-time NPS feedback on individual food choices are needed next to evaluate for causal impact of NPSs on metabolic health.
Open AccessA Nutrient Ratio–Based, Web-Enabled Food Quality Score Performs Favorably Compared with Leading Nutrient Profiling Systems for Weight and Blood Pressure
Background Obesity is on the rise, driven in part by changing patterns in food consumption. Nutrient profiling systems (NPSs) aim to guide healthier food choices through labeling and consumer facing technologies that highlight food quality. Objectives This study compares four leading NPSs—Nutri-Score (NS), Health Star (HS), NOVA Classification (NC), Food Compass 2.0 (FC) – with nutrient ratios and a nutrient-ratio-based NPS, Nutrient Consume Score (NCS), for their associations with obesity and blood pressure in the U.S. population using NHANES data. Methods NHANES (2015–2016) was analyzed for adults aged 20 and older. Dietary intake was assessed via 24-hour recalls, and NPS scores were calculated. Multivariable regression models adjusted for lifestyle factors were used to assess associations with obesity and blood pressure measures. Results All NPSs and nutrient ratios were significantly correlated with healthier weight and showed variable associations with blood pressure. Incorporating alcohol and adjusting for bioactives in a ratio-based NPS improved its association with weight outcomes. The food categories contributing to high and low scores were largely consistent across NPSs. Conclusions The NPSs and nutrient ratios evaluated were significantly associated with obesity and blood pressure measures. Intervention studies offering real-time NPS feedback on individual food choices are needed next to evaluate for causal impact of NPSs on metabolic health.
- Open Access
- 1 April 2023
- Published by Elsevier in Advances in Nutrition
- Vol. 14 (3) , 420-425
Perspective: Nutrition’s Next Chapter – Bioactive Gaps and the Microbiome–Mitochondria Axis
- 1 April 2023
- Published by Elsevier in Advances in Nutrition
- Vol. 14 (3) , 420-425
Open AccessPerspective: Nutrition’s Next Chapter – Bioactive Gaps and the Microbiome–Mitochondria Axis
- Open Access
- 23 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1203-1212
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind , randomized, placebo‐controlled trial
Aims: To investigate a prebiotic fibre‐enriched nutritional formula on health‐related quality of life and metabolic control in type 2 diabetes. Materials and Methods: This was a 12‐week, double‐blind, placebo‐controlled study with an unblinded dietary advice only comparator arm. Participants were randomized 2:1:1 to a prebiotic fibre‐enriched nutritional formula (Active), a placebo fibre‐absent nutritional formula (Placebo), or non‐blinded dietary advice alone (Diet). Primary endpoint was change in core Type 2 Diabetes Distress Assessment System (cT2‐DDAS) at week 12. Glycated haemoglobin (HbA1c) change was a key secondary endpoint. Results: In total, 192 participants were randomized. Mean age was 54.3 years, HbA1c 7.8%, and body mass index 35.9 kg/m 2 . At week 12, cT2‐DDAS reduced significantly in Active versus Placebo (−0.4, p = .03), and HbA1c was reduced significantly in Active vs Placebo (−0.64%, p = .01). Gut microbiome sequencing revealed that the relative abundance of two species of butyrate‐producing bacteria ( Roseburia faecis and Anaerostipes hadrus ) increased significantly in Active vs. Placebo. Conclusions: A microbiome‐targeting nutritional formula significantly improved cT2‐DDAS and HbA1c, suggesting the potential for prebiotic fibre as a complement to lifestyle and/or pharmaceutical interventions for managing type 2 diabetes.
- 23 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1203-1212
Open AccessA microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind , randomized, placebo‐controlled trial
Aims: To investigate a prebiotic fibre‐enriched nutritional formula on health‐related quality of life and metabolic control in type 2 diabetes. Materials and Methods: This was a 12‐week, double‐blind, placebo‐controlled study with an unblinded dietary advice only comparator arm. Participants were randomized 2:1:1 to a prebiotic fibre‐enriched nutritional formula (Active), a placebo fibre‐absent nutritional formula (Placebo), or non‐blinded dietary advice alone (Diet). Primary endpoint was change in core Type 2 Diabetes Distress Assessment System (cT2‐DDAS) at week 12. Glycated haemoglobin (HbA1c) change was a key secondary endpoint. Results: In total, 192 participants were randomized. Mean age was 54.3 years, HbA1c 7.8%, and body mass index 35.9 kg/m 2 . At week 12, cT2‐DDAS reduced significantly in Active versus Placebo (−0.4, p = .03), and HbA1c was reduced significantly in Active vs Placebo (−0.64%, p = .01). Gut microbiome sequencing revealed that the relative abundance of two species of butyrate‐producing bacteria ( Roseburia faecis and Anaerostipes hadrus ) increased significantly in Active vs. Placebo. Conclusions: A microbiome‐targeting nutritional formula significantly improved cT2‐DDAS and HbA1c, suggesting the potential for prebiotic fibre as a complement to lifestyle and/or pharmaceutical interventions for managing type 2 diabetes.
- Open Access
A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial
OBJECTIVE: To investigate a prebiotic fiber-enriched nutritional formula on health-related quality of life and metabolic control in type 2 diabetes. RESEARCH DESIGN AND METHODS: 12-week, double-blind, placebo-controlled trial. Participants were randomized 2:1:1 to a prebiotic fiber-enriched nutritional formula (Active), a placebo fiber-absent nutritional formula (Placebo), or dietary advice alone (Diet). Primary endpoint was change in core Type 2 Diabetes Distress Assessment System (cT2-DDAS) at week 12. HbA1c change was a key secondary endpoint. RESULTS: 192 participants were randomized. Mean age was 54.3 years, HbA1c 7.8%, and BMI 35.9 kg/m 2 . At week 12, cT2-DDAS (p=0.03) was reduced significantly in Active versus control arms, and HbA1c (p=0.009) was reduced significantly in Active vs Placebo arm. CONCLUSIONS: A microbiome-targeting nutritional formula significantly improved cT2-DDAS and HbA1c suggesting the potential for prebiotic fiber as a complement to lifestyle and/or pharmaceutical interventions for managing type 2 diabetes.
Open AccessA Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial
OBJECTIVE: To investigate a prebiotic fiber-enriched nutritional formula on health-related quality of life and metabolic control in type 2 diabetes. RESEARCH DESIGN AND METHODS: 12-week, double-blind, placebo-controlled trial. Participants were randomized 2:1:1 to a prebiotic fiber-enriched nutritional formula (Active), a placebo fiber-absent nutritional formula (Placebo), or dietary advice alone (Diet). Primary endpoint was change in core Type 2 Diabetes Distress Assessment System (cT2-DDAS) at week 12. HbA1c change was a key secondary endpoint. RESULTS: 192 participants were randomized. Mean age was 54.3 years, HbA1c 7.8%, and BMI 35.9 kg/m 2 . At week 12, cT2-DDAS (p=0.03) was reduced significantly in Active versus control arms, and HbA1c (p=0.009) was reduced significantly in Active vs Placebo arm. CONCLUSIONS: A microbiome-targeting nutritional formula significantly improved cT2-DDAS and HbA1c suggesting the potential for prebiotic fiber as a complement to lifestyle and/or pharmaceutical interventions for managing type 2 diabetes.
- Open Access
- 16 July 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (7) , e1008451
Updating the fungal infection-mammalian selection hypothesis at the end of the Cretaceous Period
- 16 July 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (7) , e1008451
Open AccessUpdating the fungal infection-mammalian selection hypothesis at the end of the Cretaceous Period
- 3 August 2016
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (4) , 617-624
Tropheryma whipplei infection (Whipple's disease) in a patient after liver transplantation
Whipple's disease (WD) is a rare infection caused by the bacterium Tropheryma whipplei that can affect multiple organs and most commonly occurs in the immunocompetent host. Only 3 cases of WD have been reported in the setting of immunosuppression for organ transplantation. Here, we report the first case of WD, to our knowledge, in a patient after liver transplantation with comorbid graft‐versus‐host‐disease. We discuss the diagnostic challenges in this setting and the value of electron microscopy and in situ hybridization methods for confirming the infection. WD may be under‐diagnosed in immunosuppressed transplant patients because the disease can present with atypical clinical and histological features that suggest other conditions.
- 3 August 2016
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (4) , 617-624
Tropheryma whipplei infection (Whipple's disease) in a patient after liver transplantation
Whipple's disease (WD) is a rare infection caused by the bacterium Tropheryma whipplei that can affect multiple organs and most commonly occurs in the immunocompetent host. Only 3 cases of WD have been reported in the setting of immunosuppression for organ transplantation. Here, we report the first case of WD, to our knowledge, in a patient after liver transplantation with comorbid graft‐versus‐host‐disease. We discuss the diagnostic challenges in this setting and the value of electron microscopy and in situ hybridization methods for confirming the infection. WD may be under‐diagnosed in immunosuppressed transplant patients because the disease can present with atypical clinical and histological features that suggest other conditions.
- Open Access
- 22 May 2016
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 9 (4) , 606-625
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
We discuss the tripartite pathophysiological circuit of inflammatory bowel disease (IBD), involving the intestinal microbiota, barrier function, and immune system. Dysfunction in each of these physiological components (dysbiosis, leaky gut, and inflammation) contributes in a mutually interdependent manner to IBD onset and exacerbation. Genetic and environmental risk factors lead to disruption of gut homeostasis: genetic risks predominantly affect the immune system, environmental risks predominantly affect the microbiota, and both affect barrier function. Multiple genetic and environmental ‘hits’ are likely necessary to establish and exacerbate disease. Most conventional IBD therapies currently target only one component of the pathophysiological circuit, inflammation; however, many patients with IBD do not respond to immune-modulating therapies. Hope lies in new classes of therapies that target the microbiota and barrier function.
- 22 May 2016
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 9 (4) , 606-625
Open AccessThe intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
We discuss the tripartite pathophysiological circuit of inflammatory bowel disease (IBD), involving the intestinal microbiota, barrier function, and immune system. Dysfunction in each of these physiological components (dysbiosis, leaky gut, and inflammation) contributes in a mutually interdependent manner to IBD onset and exacerbation. Genetic and environmental risk factors lead to disruption of gut homeostasis: genetic risks predominantly affect the immune system, environmental risks predominantly affect the microbiota, and both affect barrier function. Multiple genetic and environmental ‘hits’ are likely necessary to establish and exacerbate disease. Most conventional IBD therapies currently target only one component of the pathophysiological circuit, inflammation; however, many patients with IBD do not respond to immune-modulating therapies. Hope lies in new classes of therapies that target the microbiota and barrier function.
- Open Access
- 19 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0133925
Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis
Fecal microbiota transplantation (FMT) is an investigational treatment for diseases thought to involve alterations in the intestinal microbiota including ulcerative colitis (UC). Case reports have described therapeutic benefit of FMT in patients with UC, possibly due to changes in the microbiota. We measured the degree to which the transplanted microbiota engraft following FMT in patients with UC using a donor similarity index (DSI). Seven patients with mild to moderate UC (UC disease activity index scores 3–10) received a single colonoscopic administration of FMT. Metagenomic sequence data from stool were analyzed using an alignment-free comparison tool, to measure the DSI, and a phylogenetic analysis tool, to characterize taxonomic changes. Clinical, endoscopic, histologic, and fecal calprotectin outcome measures were also collected. One of 5 patients from whom sequencing data were available achieved the primary endpoint of 50% donor similarity at week 4; an additional 2 patients achieved 40% donor similarity. One patient with 40% donor similarity achieved clinical and histologic remission 1 month after FMT. However, these were lost by 2−3 months, and loss correlated with a decrease in DSI. The remaining patients did not demonstrate clinical response or remission. Histology scores improved in all but 1 patient. No patients remained in remission at 3 months after FMT. Following a single colonoscopic fecal transplant, a DSI of 40-50% is achieved in about two-thirds of recipients. This level of engraftment correlated with a temporary clinical improvement in only 1/5 patients. Larger sample sizes could further validate this method for measuring engraftment, and changes in transplant frequency or method might improve microbiota engraftment and efficacy. ClinicalTrials.gov NCT01742754
- 19 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0133925
Open AccessLow Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis
Fecal microbiota transplantation (FMT) is an investigational treatment for diseases thought to involve alterations in the intestinal microbiota including ulcerative colitis (UC). Case reports have described therapeutic benefit of FMT in patients with UC, possibly due to changes in the microbiota. We measured the degree to which the transplanted microbiota engraft following FMT in patients with UC using a donor similarity index (DSI). Seven patients with mild to moderate UC (UC disease activity index scores 3–10) received a single colonoscopic administration of FMT. Metagenomic sequence data from stool were analyzed using an alignment-free comparison tool, to measure the DSI, and a phylogenetic analysis tool, to characterize taxonomic changes. Clinical, endoscopic, histologic, and fecal calprotectin outcome measures were also collected. One of 5 patients from whom sequencing data were available achieved the primary endpoint of 50% donor similarity at week 4; an additional 2 patients achieved 40% donor similarity. One patient with 40% donor similarity achieved clinical and histologic remission 1 month after FMT. However, these were lost by 2−3 months, and loss correlated with a decrease in DSI. The remaining patients did not demonstrate clinical response or remission. Histology scores improved in all but 1 patient. No patients remained in remission at 3 months after FMT. Following a single colonoscopic fecal transplant, a DSI of 40-50% is achieved in about two-thirds of recipients. This level of engraftment correlated with a temporary clinical improvement in only 1/5 patients. Larger sample sizes could further validate this method for measuring engraftment, and changes in transplant frequency or method might improve microbiota engraftment and efficacy. ClinicalTrials.gov NCT01742754